Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess the bioequivalence of a potential generic 600 mg
oxcarbazepine tablet formulation with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet,
Trileptal, folloiwng a single 600 mg dose administered with food.